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https://doi.org/10.1186/s10194-018-0881-zRESEARCH ARTICLE Open AccessEfficacy and safety of DFN-11 (sumatriptan
injection, 3 mg) in adults with episodic
migraine: a multicenter, randomized,
double-blind, placebo-controlled study
Stephen Landy1, Sagar Munjal2*, Elimor Brand-Schieber2 and Alan M. Rapoport3Abstract
Background: In a previous randomized, double-blind, proof-of-concept study in rapidly escalating migraine, a 3 mg
dose of subcutaneous sumatriptan (DFN-11) was associated with fewer and shorter triptan sensations than a 6 mg
dose. The primary objective of the study was to assess the efficacy and safety of acute treatment with DFN-11
compared with placebo in episodic migraine.
Methods: This was a multicenter, randomized, double-blind, placebo-controlled efficacy and safety study of DFN-11 in
the acute treatment of adults with episodic migraine (study RESTOR). The primary endpoint was the proportion of subjects
taking DFN-11 who were pain free at 2 h postdose in the double-blind period compared with placebo. Secondary
endpoints included earlier postdose timepoints, assessments of pain relief and subjects’ freedom from their most
bothersome symptom (MBS) (among nausea, photophobia, and phonophobia). Safety and tolerability were assessed.
Results: A total of 392 subjects was screened, 268 (68.4%) were randomized, and 234 (87.3% of those randomized)
completed the double-blind treatment period. The proportion of subjects who were pain free at 2 h postdose was
significantly greater in the DFN-11 group than in the placebo group (51.0% vs 30.8%, P = 0.0023). Compared with
placebo, significantly higher proportions of subjects treated with DFN-11 were also pain free at 30, 60, and 90 min
postdose (P ≤ 0.0195). DFN-11 was significantly superior to placebo for pain relief at 60 min, 90 min, and 2 h postdose
(P ≤ 0.0179). At 2 h postdose, DFN-11 was also significantly superior to placebo for freedom from photophobia
(P = 0.0056) and phonophobia (P = 0.0167). Overall, 33.3% (37/111) who received DFN-11 and 13.4% (16/119)
who received placebo experienced at least 1 treatment-emergent adverse event (TEAE), the most common of
which were injection site swelling (7.2% vs 0.8%) and pain (7.2% vs 5.9%). Chest discomfort was about half as
common in the DFN-11 treatment group as it was in the placebo group (0.9% vs 1.7%).
Conclusions: This study met its primary endpoint, pain freedom at 2 h postdose, with DFN-11 significantly better
than placebo, and the incidence of TEAEs and triptan sensations with DFN-11 was low. The 3 mg dose of
sumatriptan in DFN-11 appears to be an effective alternative to a 6 mg SC dose of sumatriptan, with good safety
and tolerability. (clinicaltrials.gov: NCT02569853; registered 07 October 2015).
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Migraine is a chronic neurologic disorder characterized
by episodic attacks of head pain and associated symp-
toms, such as photophobia, phonophobia, and gastro-
intestinal disturbances; attacks are often accompanied by
cutaneous allodynia and may be preceded by an aura
and/or premonitory symptoms [1]. The International
Headache Society recognizes 2 main subtypes: episodic
migraine, with fewer than 15 headache days per month,
and chronic migraine, in which headache is present on 15
or more days per month [1]. In the United States, nearly
38 million adults have migraine [2, 3], with women about
3 times more likely to be affected than men (18% vs 6%)
[4]. For many patients, the burden of migraine includes
negative effects on performance and attendance at work,
school, family, and leisure activities. Migraineurs have an
increased likelihood of unemployment, lack of advance-
ment at work, and occupational disability, as well as
elevated risk of developing comorbid conditions (eg,
depression, anxiety and other pain disorders) [5–7].
The acute treatment of migraine may involve simple
analgesics, combination over-the-counter medications,
nonsteroidal anti-inflammatory drugs (NSAIDs), and
migraine-specific medications (eg, triptans and ergot al-
kaloids) [8–13]. Triptans are often considered the best
choice for first-line therapy [8, 9, 14]. The most rapidly
effective treatment in the class is 6 mg subcutaneous
(SC) sumatriptan [15, 16], which reaches peak plasma
concentration (tmax) in 12 min, has an onset of action of
10 min, and relieves migraine pain in 82% of patients at
2 h postdose [17]. Despite its excellent efficacy profile,
fewer than 10% of migraineurs who might benefit from
SC sumatriptan use it to treat their condition [18]. This
may be because most (59%) SC sumatriptan-treated
patients have injection site reactions, and many (42%)
experience triptan sensations (eg, tingling, warm/hot,
tightness/pressure) that appear to be dose-related [19].
Concerns about drug-related adverse events (AEs) have
caused two thirds of migraine patients to delay or avoid
treating an attack [18].
DFN-11 (Zembrace® SymTouch®, Promius Pharma,
Princeton, NJ) is a low-dose (3 mg) sumatriptan SC in-
jection supplied as a single-dose, ready-to-use, dispos-
able autoinjector [20], which distinguishes it from the
6 mg SC dose of sumatriptan (Imitrex®, GlaxoSmithK-
line, Research Triangle Park, NC). DFN-11 has less su-
matriptan per dose (3 mg vs 6 mg) and is therefore a
more dilute formulation (3 mg/0.5 mL vs 6 mg/0.5 mL)
[17, 21]. It is stable at controlled room temperature stor-
age and has a 2-year shelf life. In an earlier pilot study in
adults with rapidly escalating migraine attacks, DFN-11
was shown to be as effective as a 6 mg SC dose of suma-
triptan, and was associated with improved tolerability
[22]. Specifically, subjects who received DFN-11 hadeffective relief of migraine pain and associated symp-
toms, a lower incidence of triptan sensations, and no
chest pain [22]. The objective of the present study was
to assess the efficacy, tolerability, and safety of DFN-11
in the acute treatment of episodic migraine attacks.
Methods
Ethics
This randomized, double-blind, placebo-controlled study,
with an open-label extension, evaluated the efficacy, toler-
ability, and safety of DFN-11 in adults with episodic mi-
graine (study RESTOR). It was conducted at 17 study
centers in the United States. The protocol was approved by
the institutional review boards at each study site, and the
study was conducted in compliance with good clinical prac-
tice and in accordance with the ethical principles set forth
in the Declaration of Helsinki. Before any study-specific
procedures were initiated, investigators explained the na-
ture of the study to the subjects, and subjects provided in-
formed consent. Details about the trial are available online
at ClinicalTrials.gov (Identifier: NCT02569853).
Subjects
Subjects included males and females aged 18 to 65 years with
a history of episodic migraine with or without aura who ex-
perienced 2 to 6 migraine attacks per month for at least the
previous 12 months, with no more than 14 headache days
per month and a minimum of 48 h of headache-free time
between attacks. Individuals with aura lasting longer than
60 min were excluded. Female subjects had to have a nega-
tive serum pregnancy test at screening and all subsequent
study visits and no plans to become pregnant during the
study, and they could not be lactating. Female subjects with
male partners and male subjects with female partners had to
agree to practice a reliable form of contraception or abstin-
ence during the study.
Subjects were excluded if they had medication overuse
headache or any abnormal physiology and/or pathology
that would compromise data collection, confound the
objectives of the study, be a contraindication for study
participation, or not allow the objectives of the study to
be met. Complete exclusion criteria are provided in the
Additional file 1 (available online).
Study procedures
This study involved 5 site visits: screening, baseline/
randomization, end double-blind/begin open-label, week
4, and end of study visit.
Screened subjects who met all the inclusion and none
of the exclusion criteria were instructed by the site staff
on the proper administration of study medication and
randomized (1:1) to receive DFN-11 or placebo via SC
autoinjector in a double-blinded fashion.
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self-administered DFN-11 or placebo via SC autoinjector to
treat 1 migraine attack within 1 h of experiencing pain of
moderate to severe intensity. Subjects who experienced in-
sufficient relief from the first dose of study medication were
permitted to take a second dose of study medication or res-
cue medication if at least 2 h had elapsed since the first
dose, and they had completed electronic diary (eDiary)
ratings up to and including the 2-h postdose rating. No
more than 2 doses of study medication were allowed in any
24-h period. Rescue medications could include prescription
and nonprescription drugs (eg, NSAIDs, other acute mi-
graine medications, vitamins, herbal/dietary supplements).
At the conclusion of the double-blind treatment period,
subjects were re-assessed for eligibility before for continu-
ing into an 8-week open-label period [23].
During the study, eDiaries were used to record data in
real-time and transmit it to a web-based data storage
system. Diary assessments included onset and duration of
headache, predose severity of pain, associated symptoms
(including the most bothersome), functional disability, res-
cue medication use, and injection site reactions.
Assessments
Efficacy
The primary efficacy endpoint was the proportion of
subjects with moderate to severe predose pain who were
pain free 2 h after the taking first dose of medication,
comparing DFN-11 and placebo. Secondary efficacy vari-
ables in the double-blind treatment period included free-
dom from nausea, photophobia, and phonophobia at 10,
15, 20, 30, 60, 90 min, and 2 h postdose; pain relief at
10, 15, 20, 30, 60, 90 min, and 2 h postdose; pain freedom
at 10, 15, 20, 30, 60, and 90 min postdose); MBS ab-
sent at 10, 15, 20, 30, 60, 90 min, and 2 h postdose; sus-
tained pain freedom at 24 h (2–24 h) postdose; and use
of rescue medication or a second dose of the study
medication after 2 h (2–24 h) postdose.
Pain intensity was graded on a 4-point Likert-type [24]
scale where 0 = no pain, 1 = mild pain, 2 = moderate
pain, and 3 = severe pain. Pain free was defined in the
double-blind period as a reduction in pain intensity from
moderate or severe at baseline to none at 2 h postdose.
Pain relief was defined as a reduction from moderate or
severe baseline pain to mild or none at 2 h postdose.
The MBS was defined as the symptom associated with
migraine that was the most bothersome from among
nausea, photophobia, and phonophobia identified prior
to dosing. Freedom from the MBS was defined as the
absence of the baseline MBS at 2 h postdose. Sustained
pain freedom was defined as pain-free at 2 h postdose
with no use of rescue medication or additional study
medication and no recurrence of headache pain within 2
to 24 h postdose.Safety
The safety endpoints in this study were the proportion of
subjects with treatment-emergent AEs (TEAEs) and serious
AEs (SAEs), as well as those with changes in clinical labora-
tory tests, vital signs, and ECG. Triptan related AE terms in-
cluded, but were not limited to, tingling/prickling, dizziness/
vertigo, warm/hot/burning sensation, cold sensation, feeling
of heaviness/pressure/tightness, paresthesia, flushing, and
numbness. For injection site reactions, terms included injec-
tion site swelling, irritation, erythema, hemorrhage, pain,
and bruising.
Statistics
The randomization list was generated by study personnel
who were not involved with study conduct, and the alloca-
tion of randomization numbers to study drug kits was per-
formed by a third-party vendor. In the double-blind portion
of the study, all subjects and study personnel involved with
study conduct were blinded to the drug assignment. For
quantitative variables, descriptive statistics include the num-
ber of subjects (n), mean, standard deviation (SD), median,
minimum, and maximum. Categorical variables are summa-
rized using the number (n) and percentage (%) of subjects
for each category. All data processing, summarization, and
analyses were performed using SAS® software, Version 9.2.
Adverse events were classified using the Medical Dictionary
for Regulatory Activities (MedDRA) dictionary, Version
18.0. All concomitant medications were coded using the
World Health Organization Drug Dictionary Enhanced
(WHODDE), version Mar2015 further coded against
Anatomic Therapeutic Chemical (ATC) classification.
Multiple study populations were analyzed. Subjects
who were randomized in the double-blind period were
the basis of the subject disposition and baseline sum-
maries. Those who were randomized, received at least 1
dose of double-blind study medication, and recorded at
least 1 postdose double-blind efficacy data point were
used for the double-blind efficacy analyses.
The analyses comparing proportions were done with
1-sided Fisher’s exact test with an alpha level equal to
0.025 to determine statistical significance. Unless noted
otherwise, a last observation carried forward (LOCF) im-
putation method was applied. Baseline data were not
carried forward, and only valid data from postbaseline
assessments collected before the 2-h postdose time point
were carried forward to impute the next missing assess-
ment up to the 2-h postdose time point. Time points be-
yond 2 h postdose were not carried forward.
The analysis of safety in the double-blind treatment
period was based on data from all randomized subjects
who received at least 1 dose of study medication in the
double-blind period. The efficacy analyses were based on
postdose timepoints data captured in real-time in an eDiary
for migraine attacks treated. Safety assessment at baseline
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dose of study medication in the double-blind period.
Change from baseline was defined as the postbaseline value
minus the baseline value, and the calculations were based
on nonmissing data.
One or more interim analyses were planned for the
purpose of evaluating potential early stopping for an effi-
cacy conclusion after a minimum of 166 subjects had
completed the double-blind period and primary end-
point data were available for approximately 145 subjects.
A conservative alpha spending function was used to pre-
serve most of the type I error for the final analysis in
case the trial did not stop for an efficacy conclusion at
the interim analysis.
Results
Subjects
Sixteen sites in the United States participated and random-
ized subjects in the study. The first subject was enrolled on
21 September 2015, and the last subject completed the
study on 30 May 2017.
A total of 392 subjects was screened, 268 (68.4%) were
randomized, and 234 (87.3% of those randomized) com-
pleted the double-blind treatment period (Fig. 1). In all,
34 (12.7%) subjects discontinued from the study. Two
(0.7%) subjects discontinued from the study due to AEs
with DFN-11.
As Table 1 shows, subjects in the DFN-11 and placebo
treatment groups were demographically similar. The
mean (SD) age of the study population was 41.0 (12.4)
years, with subjects in the DFN-11 group slight older
than those assigned to receive placebo (41.9 [12.5] vs
40.2 [12.3]). Mean (SD) weight was nearly identical be-
tween those receiving DFN-11 and placebo (84.4 [23.9]Fig. 1 Disposition of subjectskg vs 84.3 [23.6] kg), as was body mass index (30.4 [8.4]
kg/m2 vs 30.7 [8.8] kg/m2). Overall, most subjects were
female (85.4%) and white (75.7%), and the DFN-11 and
placebo treatment groups had roughly equal proportions
of female (84.7% vs 86.1%, respectively) and white sub-
jects (74.8% vs 76.6%, respectively).
Efficacy
The proportion of subjects who were pain free at 2 h post-
dose— the prespecified primary endpoint (Fig. 2)— was sig-
nificantly greater with DFN-11 than placebo (51.0% vs 30.8%,
P = 0.0023); the odds ratio (95% CI) was 2.57 (1.4–4.9).
DFN-11 was also significantly superior to placebo for pain
freedom at 30 min (22.3% vs 9.9%, P = 0.0126), 60 min
(34.6% vs 19.8%, P = 0.0128), and 90 min postdose (41.3% vs
26.7%, P = 0.0195), as shown in Fig. 2. Compared with pla-
cebo, a numerically greater proportion of subjects treated
with DFN-11 reported absence of the MBS at 2 h postdose
(64.1% vs 48.1%). A post hoc analysis using observed cases
instead of LOCF imputation yielded the result that the differ-
ence between the proportion of those treated with DFN-11
and placebo for absence of the MBS was statistically signifi-
cant (65.3% vs 47.4%, P = 0.0210).
For pain relief (Fig. 3), DFN-11 was numerically superior
to placebo beginning at 15 min postdose, and the differ-
ences between treatments were significant at 60 min (67.3%
vs 47.5%, P = 0.0032); 90 min (73.1% vs 56.4%, P = 0.0093);
and 2 h postdose (76.0% vs 61.5%, P = 0.0179).
As shown in Fig. 4, DFN-11 outperformed placebo for
freedom from nausea from 20 min postdose through 2 h
postdose, and the separation was significant at 60 min post-
dose (71.1% vs 48.1%, P = 0.0178). Compared with placebo,
more subjects who were treated with DFN-11 were
photophobia-free from 15 min through 2 h postdose, and
Table 1 Demographics
DFN-11
(n = 131)
n (%)
Placebo
(n = 137)
n (%)
Overall
(N = 268)
n (%)
Age, yearsa 41.9 (12.5) 40.2 (12.3) 41.0 (12.4)
Sex
Men 20 (15.3) 19 (13.9) 39 (14.6)
Women 111 (84.7) 118 (86.1) 229 (85.4)
Race
Asian 1 (0.8) 3 (2.2) 4 (1.5)
Black/African-American 29 (22.1) 23 (16.8) 52 (19.4)
Native Hawaiian or Other Pacific Islander 0 (0.0) 2 (1.5) 2 (0.7)
White 98 (74.8) 105 (76.6) 203 (75.7)
Other 3 (2.3) 4 (2.9) 7 (2.6)
Ethnicity
Not Reported 0 (0.0) 1 (0.7) 1 (0.4)
Hispanic or Latino 10 (7.6) 9 (6.6) 19 (7.1)
Not Hispanic or Latino 121 (92.4) 127 (92.7) 248 (92.5)
Weight, kga 84.4 (23.9) 84.3 (23.6) 84.4 (23.7)
Height, cma 166.7 (8.4) 166.0 (8.7) 166.4 (8.5)
Body Mass Index, kg/m2a 30.4 (8.4) 30.7 (8.8) 30.6 (8.6)
aMean (SD)
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cant at 30 min (40.0% vs 16.4%, P = 0.0012); 60 min (48.7%
vs 27.4%, P = 0.0060); 90 min (59.2% vs 34.2%, P = 0.0019);
and 2 h postdose (64.5% vs 42.5%, P = 0.0056). Subjects in
the DFN-11 group were more likely than those in the pla-
cebo group to be phonophobia-free from 10 min through
2 h postdose, and the separations from placebo were
significant at 30 min (47.5% vs 27.9%, P = 0.0183); 60 min
(61.7% vs 38.2%, P = 0.0066); and 2 h postdose (70.0% vs
50.0%, P = 0.0167).
For sustained pain freedom from 2 through 24 h post-
dose, DFN-11 was numerically superior to placebo
(74.4% vs 66.7%), and a smaller proportion of subjectsFig. 2 Proportion of subjects with pain freedom through 2 h postdosetook a second dose of study medication or rescue medica-
tion (25.2% vs 32.8%). On these endpoints, the differences
between DFN-11 and placebo did not reach statistical
significance.
Findings from the open-label portion of the study are
beyond the scope of this manuscript and are reported
elsewhere [23].
Safety
During the double-blind treatment period, 23.0% of sub-
jects (53/230) experienced at least 1 TEAE: 33.3% (37/111)
of subjects who received DFN-11 and 13.4% (16/119) of
those treated with placebo (Table 2). Most of these subjects
Fig. 3 Proportion of subjects with pain relief through 2 h postdose
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tensity. Two subjects (1.8%) in the DFN-11 group had se-
vere AEs (1 had injection site pain, and 1 had nausea). No
subjects in the placebo group experienced severe AEs. Four
subjects, 2 in each treatment group, had AEs of unknown
severity. There were no serious AEs, but 2 subjects (0.9%)
in the DFN-11 group had AEs that led to study discontinu-
ation — worsening of migraine (not treatment-emergent)
and a subject with 2 mild TEAEs of abnormal ECG
(ventricular extrasystoles and sinus tachycardia), both of
which were considered to be unrelated to the study drug.
Injection site reactions
Table 2 shows that the most common TEAEs were associ-
ated with the injection site. In total, 17.4% (40/230) of sub-
jects reported at least 1 injection site reaction, with 23.4%
(26/111) in the DFN-11 group and 11.8% (14/119) in the
placebo group. Compared with placebo, the rate among
subjects who received DFN-11 was notably higher for in-
jection site swelling (7.2% vs 0.8%).
Triptan-related adverse events
Triptan-related AEs (Table 3) were reported by 4.3% of
subjects overall. They were generally more common
among those treated with DFN-11 than with placebo
(7.2% vs 1.7%), except for chest discomfort, which was
less common in the DFN-11 treatment group (0.9% vs
1.7%), and dyspnea, reported by 1 subject (0.8%) in the
placebo group and no subject treated with DFN-11.Discussion
DFN-11 was significantly more effective than placebo for
the primary endpoint, the proportion of pain free subjects at
2 h postdose, which is currently a guidelines-recommended
primary measure of efficacy in migraine trials [25]. Signifi-
cant separation from placebo was seen starting at 30 minpostdose, meeting both patient need for rapid migraine relief
[26, 27] and guideline recommendations for measurements
of pain freedom before 2 h postdose [25]. DFN-11 was also
significantly better than placebo for migraine pain relief
from 60 min through 2 h postdose. In addition to significant
superiority over placebo on pain free and pain relief
outcomes, DFN-11 provided significantly better relief
of the symptoms associated with migraine, including
the subject-identified MBS (in post hoc analysis). These
positive responses on multiple efficacy endpoints
suggest that DFN-11 has attributes that are clinically
important to migraine sufferers, specifically, fast and
effective relief of migraine pain and associated symp-
toms [26, 27].
As expected, the most common TEAEs were related to
the injection site, with a higher overall incidence for
DFN-11 than placebo. It is noteworthy, however, that in-
jection site reactions following DFN-11 in the current
study were 61% lower than those previously reported for
SC sumatriptan (23% vs 59%) [17]. Similarly, the incidence
of triptan sensations with the 3 mg dose of sumatriptan in
DFN-11 was low. Although not directly comparable, the
percentage of subjects with triptan sensations associated
with DFN-11 in this study was approximately 80% lower
than published estimates for the 6 mg SC dose (7.2% vs
42%), and DFN-11 demonstrated lower rates than placebo
on chest discomfort. Treatment-emergent AEs of dyspnea
and palpitations were only experienced in the placebo
group.
Administration of sumatriptan via SC injection is one op-
tion for patients in whom oral medications are suboptimal,
but needle-averse patients seeking a more rapid onset of
action than oral agents can provide may benefit from intra-
nasal sumatriptan [28]. A novel intranasal powder form is
available (ONZETRA® Xsail®, AVANIR Pharmaceuticals,
Aliso Viejo, CA, USA), and an intranasal spray (sumatrip-
tan 10 mg with a permeation-enhancing excipient) remains
Fig. 4 Proportions of subjects with freedom from nausea (a), photophobia (b), and phonophobia (c)
Landy et al. The Journal of Headache and Pain  (2018) 19:69 Page 7 of 9in development, and both of these agents have a fast onset
of action and are effective in the acute treatment of mi-
graine [29–31]. For patients in whom speed of onset is the
most important attribute of an acute migraine medication,
however, the SC injection of sumatriptan remains the fast-
est and most effective therapy.
The results of this study support the efficacy and safety
of the 3 mg autoinjector dose of sumatriptan, and they
complement the results of a previous randomized,
double-blind, crossover trial with DFN-11 [22], whichcompared the 3 mg dose with a 6 mg dose of DFN-11
[22]. In this pilot trial, a single 3 mg dose of DFN-11 pro-
vided relief of migraine pain and associated symptoms
comparable to 6 mg and was associated with fewer triptan
sensations. Achieving similar efficacy and safety results
compared with placebo in the current well-powered,
double-blind study supports that patient response to
DFN-11 is likely to be reliable and predictable.
This study met its primary efficacy endpoint and dem-
onstrated the efficacy and tolerability of DFN-11. These
Table 2 Treatment-emergent adverse events overall and
occurring in at least 2 subjects
DFN-11
(n = 111)
n (%)
Placebo
(n = 119)
n (%)
Total
(N = 230)
n (%)
Subjects with ≥1 TEAE 37 (33.3) 16 (13.4) 53 (23.0)
Subjects with ≥1 injection site reaction 26 (23.4) 14 (11.8) 40 (17.4)
Injection site pain 8 (7.2) 7 (5.9) 15 (6.5)
Injection site swelling 8 (7.2) 1 (0.8) 9 (3.9)
Injection site bruising 5 (4.5) 3 (2.5) 8 (3.5)
Injection site irritation 4 (3.6) 3 (2.5) 7 (3.0)
Injection site erythema 2 (1.8) 1 (0.8) 3 (1.3)
Injection site induration 2 (1.8) 0 (0.0) 2 (0.9)
Paresthesia 3 (2.7) 0 (0.0) 3 (1.3)
Nausea 2 (1.8) 0 (0.0) 2 (0.9)
Throat tightness 2 (1.8) 0 (0.0) 2 (0.9)
Chest discomfort 1 (0.9) 2 (1.7) 3 (1.3)
TEAE, treatment-emergent adverse event
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the 3 mg sumatriptan SC autoinjector for the acute treat-
ment of migraine, should be useful in predicting response
to DFN-11 in clinical practice. Limitations of the study
include the high placebo response and the inability of a
single-attack, parallel-group design to detect fluctuations
in treatment response across multiple attacks. Future
studies, are needed to further clarify the clinical utility and
therapeutic potential of DFN-11.
Conclusions
In this multicenter, randomized, double-blind, placebo-con-
trolled study in adults with episodic migraine, DFN-11 was
significantly more effective than placebo on multiple pain
free and pain relief assessments from 30 min through 2 hTable 3 Triptan-related adverse events
DFN-11
(n = 111)
n (%)
Placebo
(n = 119)
n (%)
Total
(N = 230)
n (%)
Subjects with ≥1 triptan-related AE 8 (7.2) 3 (2.5) 11 (4.8)
Palpitations 0 (0.0) 1 (0.8) 1 (0.4)
Nausea 2 (1.8) 0 (0.0) 2 (0.9)
Chest discomfort 1 (0.9) 2 (1.7) 3 (1.3)
Dizziness 1 (0.9) 0 (0.0) 1 (0.4)
Lethargy 1 (0.9) 0 (0.0) 1 (0.4)
Paresthesia 3 (2.7) 0 (0.0) 3 (1.3)
Dyspnea 0 (0.0) 1 (0.8) 1 (0.4)
Throat irritation 1 (0.9) 0 (0.0) 1 (0.4)
Throat tightness 2 (1.8) 0 (0.0) 2 (0.9)
AE, adverse eventpostdose and the relief of migraine associated symptoms,
including the subjects’ MBS. Taken together with the low
incidence of TEAEs and triptan sensations, these findings
demonstrate that the 3 mg dose of sumatriptan in DFN-11
may be a useful alternative to the 6 mg SC dose of
sumatriptan.
Additional file
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